CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 93 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $154,000 | -81.6% | 17,500 | -68.9% | 0.08% | +70.8% |
| Q3 2018 | $835,000 | -48.9% | 56,297 | -42.1% | 0.05% | -50.0% |
| Q2 2018 | $1,635,000 | -50.6% | 97,200 | -32.8% | 0.10% | -54.7% |
| Q1 2018 | $3,311,000 | +83.1% | 144,600 | -19.2% | 0.21% | +44.2% |
| Q3 2016 | $1,808,000 | -41.1% | 178,900 | -34.6% | 0.15% | -48.8% |
| Q2 2016 | $3,070,000 | -25.9% | 273,400 | -9.9% | 0.29% | -31.5% |
| Q1 2016 | $4,145,000 | -29.8% | 303,500 | -2.5% | 0.42% | -44.3% |
| Q4 2015 | $5,903,000 | +2.8% | 311,200 | +1.6% | 0.75% | +0.8% |
| Q3 2015 | $5,743,000 | +125.0% | 306,300 | +78.7% | 0.75% | +109.0% |
| Q2 2015 | $2,552,000 | +64.9% | 171,400 | +67.5% | 0.36% | +65.3% |
| Q1 2015 | $1,548,000 | +5.4% | 102,300 | -7.4% | 0.22% | -12.6% |
| Q4 2014 | $1,468,000 | +75.0% | 110,500 | +65.4% | 0.25% | +96.0% |
| Q3 2014 | $839,000 | +459.3% | 66,800 | +348.3% | 0.13% | +472.7% |
| Q2 2014 | $150,000 | -40.2% | 14,900 | -20.3% | 0.02% | -43.6% |
| Q1 2014 | $251,000 | – | 18,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 968,198 | $9,634,000 | 3.29% |
| INGALLS & SNYDER LLC | 1,382,048 | $13,751,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 700,710 | $6,972,000 | 0.66% |
| Alambic Investment Management, L.P. | 17,900 | $178,000 | 0.45% |
| RA Capital Management | 1,858,474 | $18,492,000 | 0.36% |
| Perceptive Advisors | 2,150,641 | $21,398,000 | 0.35% |
| Eversept Partners, LP | 232,983 | $2,318,181 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 17,351 | $173,000 | 0.10% |
| Alyeska Investment Group, L.P. | 502,783 | $5,003,000 | 0.08% |
| KENNEDY CAPITAL MANAGEMENT LLC | 263,958 | $2,626,000 | 0.08% |